Article

How to perform transperineal saturation prostate biopsy

Author(s):

Willet F. Whitmore, III, MD,Winston E. Barzell, MD

The inherent limitations of the standard transrectal ultrasound approach for prostate biopsy have led to both diagnostic and therapeutic dilemmas.

Related Videos
Mohamad Baker Berjaoui, MD, answers a question during a Zoom video interview
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
Justin Dubin, MD, answers a question during a video interview
Phillip M. Pierorazio, MD, answers a question during a video interview
Related Content
Human urinary bladder | Image Credit: © magicmine - stock.adobe.com
December 5th 2024

BOND-003: Cretostimogene yields high CR rate, is well tolerated in NMIBC

Benjamin P. Saylor Hannah Clarke
The overall complete response rate was 74.5% (95% CI, 65.4%-82.4%).
Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults
November 27th 2024

Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults

Wayne Kuang, MD Bilal Chughtai, MD
Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.
FDA fast tracks PT217 for neuroendocrine prostate cancer
December 5th 2024

FDA fast tracks PT217 for neuroendocrine prostate cancer

Hannah Clarke
PT217 is currently under investigation in the phase 1/2 SKYBRIDGE trial in patients with neuroendocrine cancers.
Former MLB player Dave Winfield shares lessons from baseball, philanthropy
November 15th 2024

Former MLB player Dave Winfield shares lessons from baseball, philanthropy

Urology Times staff
In this episode of Speaking of Urology, former MLB player Dave Winfield shares lessons he’s learned throughout his professional baseball career and his work in philanthropy.
The potential of HER2 targeting in prostate cancer: A case study with trastuzumab deruxtecan
December 4th 2024

The potential of HER2 targeting in prostate cancer: A case study with trastuzumab deruxtecan

Maneesh R. Jain, MD
"That pan-tumor approval and this patient case really highlight that in prostate cancer, we should be checking HER2 by immunohistochemistry," says Maneesh R. Jain, MD.
JANX007 demonstrates encouraging clinical activity in mCRPC
December 3rd 2024

JANX007 demonstrates encouraging clinical activity in mCRPC

Hannah Clarke
Data showed that all patients achieved a PSA decline of at least 50%.
© 2024 MJH Life Sciences

All rights reserved.